Amgen has appointed Tony Hooper as its new Executive Vice President of Global Commercial Operations.
The 56-year-old joins from Bristol-Myers Squibb and will take on the responsibility for the companies commercial operations around the globe.
Robert Bradway, President and Chief Operating Officer, says Mr Hooper’s “passion for serving patients across the globe make him an outstanding addition”.
He joins after 16 years at BMS where he led the commercial business in the US, Asia, Middle East, Africa, South America and Europe. Most recently he served as the Senior Vice President, Commercial Operations and President, United States, Japan and Intercontinental.
“It's a privilege to join Amgen, a Company well-known for scientific innovation and developing life-changing therapies for people with serious illnesses,” said Mr Hooper. “I am looking forward to bringing my global commercial experience to Amgen as it moves to implement its strategic vision for growth and international expansion.”
On the same day at Hooper’s appointment, Amgen decided to cut 380 R&D jobs.
Share this article: